Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration.

@article{Rosenfeld2005MaximumTD,
  title={Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration.},
  author={Philip J. Rosenfeld and Steven D Schwartz and Mark Scott Blumenkranz and Joan W Miller and Julia A. Haller and James D Reimann and William L Greene and Naveed Shams},
  journal={Ophthalmology},
  year={2005},
  volume={112 6},
  pages={1048-53}
}
PURPOSE To investigate the maximum tolerated dose of ranibizumab administered as a single intravitreal injection. DESIGN Open-label, 5-center, uncontrolled, prospective, dose-ranging, interventional case series. PARTICIPANTS Twenty-seven patients with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) with best-corrected Snellen equivalent visual acuity (VA) of 20/100 or worse and considered ineligible for laser photocoagulation or photodynamic… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 95 extracted citations

Similar Papers

Loading similar papers…